Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
C Rodriguez-Mogeda, ZYGJ van Lierop… - Journal of …, 2023 - Springer
Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B
cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis …
cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis …
B-Cell Receptor Repertoire: Recent Advances in Autoimmune Diseases
Q Wang, D Feng, S Jia, Q Lu, M Zhao - Clinical Reviews in Allergy & …, 2024 - Springer
In the field of contemporary medicine, autoimmune diseases (AIDs) are a prevalent and
debilitating group of illnesses. However, they present extensive and profound challenges in …
debilitating group of illnesses. However, they present extensive and profound challenges in …
Repeated iv anti‐CD20 treatment in multiple sclerosis: Long‐term effects on peripheral immune cell subsets
J Feige, T Moser, K Akgün, K Schwenker… - Annals of Clinical …, 2024 - Wiley Online Library
Objective Repeated intravenous administration of anti‐CD20 depleting monoclonal
antibodies 6 months apart is among the highly effective treatment options in multiple …
antibodies 6 months apart is among the highly effective treatment options in multiple …
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8+ T-Cell Proliferation in Patients With Multiple Sclerosis
G Abbadessa, MT Lepore, S Bruzzaniti… - Neurology …, 2024 - AAN Enterprises
Background and Objectives The role of B cells in the pathogenic events leading to relapsing
multiple sclerosis (R-MS) has only been recently elucidated. A pivotal step in defining this …
multiple sclerosis (R-MS) has only been recently elucidated. A pivotal step in defining this …